Published on 02/12/2025

Integrating SUS E&L into PPQ and CPV

In the pharmaceutical and biopharmaceutical industries, ensuring the safety and efficacy of products is paramount. One critical aspect of this process is the evaluation of extractables and leachables (E&L) from packaging and delivery systems, particularly single-use systems (SUS) such as filters, bags, and other components. This guide outlines a step-by-step approach for integrating E&L assessments into the Product Performance Qualification (PPQ) and Continuous Process Verification (CPV) processes, mentioning relevant regulations from the FDA, EMA, and other bodies.

Understanding Extractables and Leachables

Extractables and leachables refer to the chemical substances that can migrate from packaging materials into drug products. This migration can occur during manufacturing, storage, and even during the administration of the product. The ability to identify and quantify these substances is critical to ensuring patient safety and compliance with regulatory requirements.

The drug manufacturing process must consider the nature of the packaging systems to mitigate risks associated with E&L. Therefore, a comprehensive risk assessment must be conducted, focusing on components such as filters and single-use systems. The analytical evaluation threshold (AET) and the dose-based threshold (DBT) are essential tools in evaluating the potential risk posed by these compounds.

Regulatory Framework Surrounding E&L Assessment

The regulatory landscape concerning extractables and leachables is evolving. Key agencies including the FDA, the EMA, and the MHRA have reserved stringent guidelines for assessing these risks in the pharmaceutical industry. These include guidance documents such as the PQRI guideline and considerations set forth in the EU GMP Annex 1.

These guidelines typically focus on two main aspects: the extraction of chemical compounds from materials during laboratory testing (extractables) and the leaching of these materials into final pharmaceutical products during routine use. It is crucial for companies to comply with these regulations throughout the product lifecycle, from development to commercial manufacturing.

Step 1: Identification of critical components

The process of validating single-use systems involves first identifying the components that are critical for the storage and delivery of the pharmaceutical product. This includes filters, bags, and tubing. The first step is to delineate which components are likely to interact with the drug product and could potentially leach substances into it.

• Filters: Widely used in biopharmaceutical processes to clarify and sterilize liquids. The materials used in filter construction can be a source of E&L.
• Bags: Used for storage and transport, these can also release compounds into the product.
• Other components: Such as connectors, tubing, and any apparatus that comes into contact with the drug substance.

Once identified, these components should be cataloged for further risk assessment. This cataloging may be aligned with existing databases, taking a close consideration of the materials’ chemical properties, prior extraction studies, and any toxicological data available.

Step 2: Conducting E&L Risk Assessment

The next step is to conduct an E&L risk assessment which involves comprehensive testing and evaluation. The risk assessment should cover the following stages:

2.1 Initial Screening

This step involves a preliminary analysis to identify potential extractables based on the materials used. Moreover, any previous data available from similar systems or materials should be reviewed. This helps in preliminary risk estimation.

2.2 Analytical Methods Selection

Depending on the risk profiles, appropriate analytical methods must be chosen to quantify extractables. Methods such as Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS) are commonly used, and should be well-established and validated methods that comply with current standards.

2.3 AET and DBT Calculations

The calculated AET and DBT are crucial in determining if the levels of any identified E&L exceed acceptable limits. AET is derived from the toxicological assessment, while DBT considers the drug dosage. These calculations help in comparing the concentrations of E&L against established safety thresholds.

Step 3: Generating Comprehensive Reports

Each stage of the validation process should be documented meticulously. The final reports need to include the results of the E&L tests, AET and DBT calculations, and any supporting data used to derive conclusions. This comprehensive documentation serves as a foundation for compliance during internal and external audits. It also aids in continuous improvement efforts.

Step 4: Integration into PPQ and CPV

After concluding the E&L risk assessment, the next step involves integrating findings into the PPQ and CPV processes. This integration pertains to:

4.1 PQ Protocol Development

The Product Performance Qualification protocol elucidates how E&L considerations will affect the manufacturing process, including critical quality attributes and process parameters. It is essential to detail specific actions taken in the event of exceedances in extractable limits.

4.2 Continuous Monitoring and Verification

Once implemented, ongoing monitoring becomes a crucial part of the CPV strategy. This entails establishing a robust schedule for periodic testing and evaluation of E&L performance based on initial qualification results. Additionally, any changes in the manufacturing process or materials must be assessed for potential impact on E&L profiles.

Step 5: Ensuring Container Closure Integrity (CCI)

Equally important is the assessment of container closure integrity (CCI). CCI plays a vital role in maintaining the sterility and stability of the drug product throughout its shelf life. The USP’s guidance outlines methods for CCI testing, which should be integrated with E&L assessments in a holistic validation approach.

5.1 Testing Methodologies

Several methodologies exist for CCI testing, including helium leak testing, pressure decay testing, and more recently, non-destructive techniques such as laser-based testing. It is vital to match the test method to the specific characteristics of the container closure system used.

5.2 Documentation and Compliance

Similar to E&L documentation, CCI testing results should be continuously recorded and monitored. This data also contributes to the overall compliance framework, necessary for regulatory inspections under the FDA, EMA, and MHRA guidelines.

Step 6: Validation During Manufacturing Scale-up

During the transition from development to full-scale manufacturing, the validation practices initiated in the PPQ phase should be further reinforced. This scale-up needs careful monitoring to ensure that quality parameters are met consistently.

Validation protocols should realign as equipment, processes, and personnel may change during scale-up phases. Continuous engagement with the CMC (Chemistry, Manufacturing, and Controls) team will ensure that all changes are documented and assessed for their impact on E&L qualifications.

Conclusion

The integration of extractables and leachables assessments into Product Performance Qualification and Continuous Process Verification is a complex yet critical component of pharmaceutical validation. By following the outlined steps, pharmaceutical organizations can ensure that the safety, quality, and efficacy of their products remain uncompromised.

With stringent adherence to the guidelines provided by regulatory authorities such as the FDA, EMA, and MHRA, organizations can navigate the complexities of E&L assessments effectively. By implementing a structured approach towards E&L and CCI practices, pharmaceutical companies can not only ensure regulatory compliance but also enhance patient safety and product integrity.